The U.S. Department of Justice announced Wednesday it has filed a False Claims Act complaint against Regeneron Pharmaceuticals, alleging that the company “fraudulently inflated Medicare reimbursement rates” for its eye therapy Eylea (aflibercept).
Tag Archive for: diabetic retinopathy
The FDA has expanded the label of Regeneron’s blockbuster eye therapy Eylea (aflibercept), allowing the administration of a higher 8-mg dose at up to 16-week intervals, the company announced Friday.
Citing issues with a third-party contractor, the FDA rejected Regeneron’s regulatory application for a higher-dose regimen of Eylea, the company’s blockbuster eye injection treatment.
The alliance will combine this technology with Boehringer’s research and development expertise to develop a first-in-class treatment for patients with eye diseases, Surrozen announced.